Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 4, 2015, Pages 406-416

  Dickinson, L ^a   Amin, J ^b   Else, L ^a   Boffito, M ^c   Egan, D ^a   Owen, A ^a   Khoo, S ^a   Back, D ^a   Orrell, C ^d   Clarke, A ^e   Losso, M ^f   Phanuphak, P ^e   Carey, D ^b   Cooper, D A ^b   Emery, S ^b   Puls, R ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Chelsea and Westminster Foundation Trust   (United Kingdom)

^d Institute of Infectious Disease and Molecular Medicine   (South Africa)

^e THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^f HOSPITAL RAMOS MEJÍA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; EFAVIRENZ; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; BIOLOGICAL MARKER; CYP2A6 PROTEIN, HUMAN; CYP2B6 PROTEIN, HUMAN; CYP3A43 PROTEIN, HUMAN; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNSPECIFIC MONOOXYGENASE;

ADULT; AFRICAN; AGED; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; ASIAN; ATAXIA; BODY WEIGHT; CEREBELLUM DISEASE; DEMOGRAPHY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PRIORITY JOURNAL; SEIZURE; SOMNOLENCE; UNPLEASANT DREAM; ADOLESCENT; BIOLOGICAL MODEL; BLOOD; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM; MIDDLE AGED; NONLINEAR SYSTEM; PATHOGENICITY; PHARMACOGENETICS; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; BIOMARKERS; CYTOCHROME P-450 CYP2A6; CYTOCHROME P-450 CYP2B6; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84952787102     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.156     Document Type: Article

References (41)

1. World Health Organisation. Global update on HIV treatment 2013: results, impact and opportunities. (2013). Accessed 10 September 2014.
2. World Health Organisation. Key facts on global HIV epidemic and progress in 2010. (2011). Accessed 9 September 2014.
3. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. (2013). Accessed 9 September 2014.
4. Haas, D. W. et al. A phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efavirenz in combination with open-label zidovudine with lamivudine at 36 weeks [DMP 266-005]. The XII International AIDS Conference, Geneva, Switzerland. Abstract 22334 (1998).
5. Puls, R. et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomized, double-blind, placebo-controlled, non-inferiority trial. Lancet 383, 1474-1482 (2014).
6. Hill, A. Optimizing HIV treatment. Curr. Opin. HIV AIDS 8, 34-40 (2013).
7. Cortes, C. P., Siccardi, M., Chaikan, A., Owen, A., Zhang, G. & la Porte, C. J. Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. Ther. Drug Monit. 35, 78-83 (2013).
8. Kwara, A., Lartey, M., Sagoe, K. W., Rzek, N. L. & Court, M. H. CYP2B6 (c. 516G->T) and CYP2A6 (9B and/or 17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIVinfected patients. Br. J. Clin. Pharmacol. 67, 427-436 (2009).
9. Mukonzo, J. K. et al. A novel polymorphism in ABCB1 gene, CYP2B66 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br. J. Clin. Pharmacol. 68, 690-699 (2009).
10. Wyen, C. et al. Impact of CYP2B6 983T>C polymorphism on nonnucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J. Antimicrob. Chemother. 61, 914-918 (2008).
11. Gutierrez, F. et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin. Infect. Dis. 41, 1648-1653 (2005).
12. Marzolini, C., Telenti, A., Decosterd, L. A., Greub, G., Biollaz, J. & Buclin, T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15, 71-75 (2001).
13. Rotger, M. et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15, 1-5 (2005).
14. Arab-Alameddine, M. et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin. Pharmacol. Ther. 85, 485-494 (2009).
15. Nyakutira, C. et al. High prevalence of the CYP2B6 516G->T(6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur. J. Clin. Pharmacol. 64, 357-365 (2008).
16. di Iulio, J. et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet. Genomics 19, 300-309 (2009).
17. Olagunju, A. et al. CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients. Ther. Drug Monit. 36, 734-738 (2014).
18. Swart, M., Whitehorn, H., Ren, Y., Smith, P., Ramesar, R. S. & Dandara, C. PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. BMC Med. Genet. 13, 112 (2012).
19. Holzinger, E. R. et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet. Genomics 22, 858-867 (2012).
20. Mukonzo, J. K. et al. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. PloS One 9, e86919 (2014).
21. Decloedt, E. H. & Maartens, G. Neuronal toxicity of efavirenz: A systematic review. Expert Opin. Drug Saf. 12, 841-846 (2013).
22. Kenedi, C. A. & Goforth, H. W. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 15, 1803-1818 (2011).
23. Clifford, D. B. et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann. Intern. Med. 143, 714-721 (2005).
24. Siccardi, M. et al. Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model. Clin. Pharmacol. Ther. 92, 494-502 (2012).
25. Tovar-y-Romo, L. B. et al. Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J. Pharmacol. Exp. Ther. 343, 696-703 (2012).
26. Winston, A. et al. Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomised controlled trial. Clin. Infect. Dis. 60, 1026-1032 (2015).
27. Bristol-Myers Squibb Company. Sustiva (efavirenz) capsules and tablets for oral use: highlights of prescribing information. (2014). Accessed 19 August 2014.
28. Gallant, J. E. et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354, 251-260 (2006).
29. Wyen, C. et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J. Antimicrob. Chemother. 66, 2092-2098 (2011).
30. Gatanaga, H. et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 6 and 26. Clin. Infect. Dis. 45, 1230-1237 (2007).
31. Sukasem, C. & Sungkanuparph, S. Would a CYP2B6 test help HIV patients being treated with efavirenz Pharmacogenomics 14, 999-1001 (2013).
32. Lubomirov, R. et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: An observational cohort study. J. Infect. Dis. 203, 246-257 (2011).
33. Regazzi, M., Carvalho, A. C., Villani, P. & Matteelli, A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Clin. Pharmacokinet. 53, 489-507 (2014).
34. Hill, A., Khoo, S. & Back, D. The induction effect of rifampicin on efavirenz is time-dependent: systematic review of 12 drug interaction studies. International Workshop on HIV Clinical Pharmacology, Washington DC. Abstract P29 (2014).
35. Luetkemeyer, A. F. et al. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin. Infect. Dis. 57, 586-593 (2013).
36. World Health Organisation. Technical update on treatment optimization. Use of efavirenz during pregnancy: A public health perspective. (2012). Accessed 9 September 2014.
37. Hill, A., Ford, N., Boffito, M., Pozniak, A. & Cressey, T. R. Does pregnancy affect the pharmacokinetics of efavirenz AIDS 28, 1542-1543 (2014).
38. Olagunju, A. et al. Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics. Clin. Pharmacol. Ther. 97, 298-306 (2014).
39. Amara, A. B., Tjia, J., Dutton, J., Else, L. J., Back, D. J. & Khoo, S. Development and validation of a HPLC-MS/MS assay to quantify the antiretroviral (ARV) drug, efavirenz and its major metabolites in plasma. British Mass Spectrometry Society Meeting, Cardiff, UK. Abstract BMS S11-1240 (2011).
40. Olagunju, A. et al. CYP3A422 (c. 522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. Pharmacogenet. Genomics 24, 459-463 (2014).
41. Beal, S. & Sheiner, L. B. NONMEM Users Guide. ICON Development Solutions, Ellicott City, Maryland (1989-1998). 42. Kappelhoff, B. S. et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin. Pharmacokinet. 44, 849-861 (2005).